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Background: Tiotropium + olodaterol has demonstrated improvements beyond lung function 
benefits in a large Phase III clinical program as a once-daily maintenance treatment for COPD 
and may be a potential option for the initiation of maintenance treatment in COPD. Despite 
guideline recommendations that combined long-acting β
2
-agonists and inhaled corticosteroids 
should only be used in individuals at high risk of exacerbation, there is substantial use in individu-
als at lower risk. This raises the question of the comparative effectiveness of this combination 
as maintenance treatment in this group compared to other combination regimens.
Objective: The study aimed to assess the effect on lung function of once-daily tiotropium + 
olodaterol versus twice-daily salmeterol + fluticasone propionate in all participants with Global 
initiative for chronic Obstructive Lung Disease 2 or 3 (moderate to severe) COPD.
Methods: This was a randomized, double-blind, double-dummy, four-treatment, complete 
crossover study in which participants received once-daily tiotropium + olodaterol (5/5 µg and 
2.5/5 µg) via Respimat® and twice-daily salmeterol + fluticasone propionate (50/500 µg and 
50/250 µg) via Accuhaler® for 6 weeks. The primary end point was change in forced expiratory 
volume in 1 second (FEV
1
) area under the curve from 0 hour to 12 hours (AUC
0–12
) relative to 
the baseline after 6 weeks.
Results: Tiotropium + olodaterol 5/5 µg and 2.5/5 µg demonstrated statistically significant 
improvements in FEV
1
 AUC
0–12
 compared to salmeterol + fluticasone propionate (improvements 
from baseline were 317 mL and 295 mL with tiotropium + olodaterol 5/5 µg and 2.5/5 µg, and 
188 mL and 192 mL with salmeterol + fluticasone propionate 50/500 µg and 50/250 µg, respec-
tively). Tiotropium + olodaterol was superior to salmeterol + fluticasone propionate in lung function 
secondary end points, including FEV
1
 area under the curve from 0 hour to 24 hours (AUC
0–24
).
Conclusion: Once-daily tiotropium + olodaterol in participants with moderate-to-severe 
COPD provided superior lung function improvements to twice-daily salmeterol + fluticasone 
propionate. Dual bronchodilation can be considered to optimize lung function in individuals 
requiring maintenance treatment for COPD.
Keywords: COPD, maintenance treatment, lung function, tiotropium, FEV
1
, inhaled 
corticosteroid
Introduction
In addition to smoking cessation and nonpharmacologic interventions, including pul-
monary rehabilitation, maintenance pharmacotherapy is well established for the man-
agement of COPD to optimize lung function and improve symptoms.1,2 Tiotropium is a 
once-daily COPD maintenance treatment for which there is a broad evidence base that 
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has demonstrated long-term improvements in lung function, 
quality of life, exacerbation risk, and exercise capacity,3–7 with 
a similar safety profile when delivered via the HandiHaler® 
and Respimat® inhalers.8 The benefits of tiotropium + olo-
daterol as a once-daily maintenance treatment in COPD have 
been demonstrated in two large Phase III studies (TONADO® 
1 and 2) in participants with a wide range of airway limitation 
(moderate to very severe).9 Tiotropium + olodaterol demon-
strated improvements in lung function, health-related quality 
of life, and rescue medication use compared to tiotropium and 
olodaterol individually over 52 weeks.9 In a further Phase III 
study – VIVACITO® – pulmonary function testing (PFT) was 
performed over 24 hours and results demonstrated improve-
ments in lung function over the full 24-hour dosing interval 
with tiotropium + olodaterol compared to the individual 
therapies.10 As well as demonstrating efficacy improvements, 
these Phase III studies showed that the tolerability profile 
of tiotropium + olodaterol is similar to that of tiotropium 
monotherapy.9,10
Inhaled corticosteroid (ICS) + long-acting β
2
-agonist 
(LABA) is an option for maintenance treatment that is 
recommended only for individuals who are at high risk of 
exacerbation, characterized as Global initiative for chronic 
Obstructive Lung Disease (GOLD) groups C and D, although 
prospective studies showing improved outcomes with this 
treatment regimen for these individuals are lacking.2 These 
individuals typically, though not exclusively, have severe or 
very severe airflow limitation (forced expiratory volume in 
1 second [FEV
1
] 50% predicted, GOLD 3 and 4 spirometric 
classification).2 ICS + LABA is also an option for those with 
Asthma–COPD Overlap Syndrome.11
In clinical practice, however, ICS + LABA is also com-
monly used as maintenance treatment for individuals with 
low exacerbation risk who have less severe COPD, despite 
a lack of evidence to show that this is the optimal treatment 
approach for this group.12–14 For instance, the TONADO® 
studies investigated the efficacy and safety of tiotropium + 
olodaterol over a period of 1 year, including FEV
1
 area under 
the curve (AUC) from 0 hour to 3 hours (AUC
0–3
) response, 
trough FEV
1
, and St George’s Respiratory Questionnaire 
score. In these studies, 38.4% of participants who were cat-
egorized as GOLD A or B, based on spirometry and prior 
exacerbation history, were receiving an ICS-containing treat-
ment at baseline.15 The safety profile of ICS also needs to 
be considered, due to the association with increased adverse 
events (AEs), such as pneumonia, and increased risk of 
fracture with long-term exposure.2,16
Given the increasing number of treatment options 
available, clinicians must decide the approach that is most 
appropriate for individuals who require initiation of main-
tenance treatment for COPD. Because several studies have 
shown the benefit of long-acting muscarinic antagonist 
(LAMA) or LABA monotherapy,3–7,17–19 we wished to test 
whether LAMA + LABA combination therapy would be 
more efficacious than a single agent. Therefore, in this study, 
we investigated the 24-hour lung function profile of once-
daily tiotropium + olodaterol delivered via the Respimat® 
inhaler compared to two commonly used doses of twice-
daily salmeterol + fluticasone propionate via Accuhaler® 
after 6 weeks, to assess the approach that was most effective 
at optimizing lung function. The results of this study have 
been reported previously at the European Respiratory Society 
International Conference 2015.20
Materials and methods
Study design
ENERGITO® was a Phase IIIb, multicenter, multinational, 
randomized, double-blind, double-dummy, active-controlled, 
four-treatment, complete crossover study to compare the 
effect, on the lung function profile, of orally inhaled once-
daily tiotropium + olodaterol (5/5 µg and 2.5/5 µg) via 
Respimat® compared to twice-daily salmeterol + fluticasone 
propionate (50/500 µg and 50/250 µg) via Accuhaler® after 
6 weeks of treatment in participants with COPD. The trial 
was registered with ClinicalTrials.gov under official identi-
fier NCT01969721.
The primary end point was the response (change from 
baseline) in terms of FEV
1
 AUC from 0 hour to 12 hours 
(AUC
0–12
) after 6 weeks of treatment. The key secondary 
end point was response in terms of FEV
1
 AUC from 0 hour 
to 24 hours (AUC
0–24
).
Other secondary end points were response in terms of 
FEV
1
 AUC from 12 hours to 24 hours (AUC
12–24
), peak 
FEV
1
 from 0 hour to 3 hours (peak
0–3
 FEV
1
) response, and 
trough FEV
1
 response. The primary safety end point was the 
incidence of AEs.
Further end points were trough forced vital capacity 
(FVC) response; peak
0–3
 FVC response; FVC AUC
0–24
, FVC 
AUC
0–12
, and FVC AUC
12–24
 responses; and FEV
1
 and FVC 
measured at all time points after 6 weeks of treatment.
Eligible participants entered a 4-week screening period 
during which prescription corticosteroids (inhaled or oral), 
β-adrenergics (inhaled short- or long-acting, oral or patch, except 
for β-blockers), and long-acting anticholinergics were discon-
tinued. Participants were then randomized into the crossover 
part of the study and received each of the four treatments – 
tiotropium + olodaterol 5/5 µg and 2.5/5 µg and salmeterol + 
fluticasone propionate 50/500 µg and 50/250 µg – for a period 
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of 6 weeks in a randomized sequence, with each treatment 
separated by a 21-day washout (Figure 1).
Participants entered a 21-day follow-up period after study 
completion or discontinuation, during which they were per-
mitted to resume medications prescribed prior to the study. 
Open-label salbutamol was provided for rescue medication 
use, which was recorded by the participant. A short-acting 
anticholinergic (ipratropium bromide) was provided for use 
during the screening and washout periods.
Patients
All participants provided signed, informed consent in compli-
ance with the guidelines of the International Conference on 
Harmonisation of Technical Requirements for Registration 
of Pharmaceuticals for Human Use, Harmonised Tripartite 
Guideline E6: Good Clinical Practice. The trial was initiated 
after the protocol, informed consent, and patient information 
forms were approved by the local Institutional Review Boards 
or Independent Ethics Committees for the European Union by 
the Competent Authority and, for the other counties, approval 
by, or notification to, local health authorities. Inclusion 
criteria were as follows: a diagnosis of COPD; moderate-
to-severe pulmonary impairment (postbronchodilator FEV
1
 
30% and 80% of predicted normal);21 postbronchodilator 
FEV
1
/FVC 70% at screening visit; age 40 years; current 
or ex-smoker with a smoking history of 10 pack-years; able 
to perform technically acceptable PFT and maintain paper 
diaries as required; and able to competently inhale medication 
from the Respimat® inhaler (a metered-dose inhaler) and the 
Accuhaler®. Participants were excluded if they met any of the 
following criteria: significant disease other than COPD; any 
COPD exacerbation requiring treatment with antibiotics, 
systemic steroids, or hospitalization in the past 3 months; 
abnormal laboratory tests according to the investigator; or 
a history of asthma. Additional exclusion criteria are 
summarized in Table S1. Participants were entered into the 
study based on moderate-to-severe pulmonary impairment 
(GOLD 2–3) graded according to the 2010 version of the 
GOLD strategy document.22 Information on symptoms and 
prior exacerbation history was not collected for screening 
purposes; therefore, participants were not screened based on 
the updated GOLD A–D patient group classification.2
Treatment schedule
Each morning, participants self-administered two puffs of 
the Respimat® (tiotropium + olodaterol 5/5 µg or 2.5/5 µg or 
placebo) followed by one puff of the Accuhaler® (salmeterol + 
fluticasone propionate 50/500 µg or 50/250 µg or placebo). 
Each evening (12 hours after the morning dose), participants 
inhaled one puff of the Accuhaler® only. Self-administration 
of medication was performed under supervision during 
clinic visits and the time of administration was recorded for 
accurate timing of postdose PFT. The timing of medication 
dosing was established at the start of each treatment period, 
and subsequent doses were administered within 30 minutes 
of the first dose time (ie, at 24 hours ±30 minutes).
assessments
At the screening visit, in addition to physical examination 
and laboratory testing, participants underwent reversibility 
testing using 400 µg salbutamol and received training in use 
of the devices. At the start of the treatment periods, predose 
PFT was performed at 1 hour and at 10 minutes prior to 
inhalation of trial medication for the first treatment period, 
then at 30 minutes before dosing at the start of subsequent 
treatment periods. Postdose PFT at the start of all treatment 
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Figure 1 Study design.
Notes: Treatment periods are 6 weeks and washout periods are 3 weeks. a–D refer to treatment groups.
Abbreviations: R, randomization; S, screening.
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periods was performed at 30 minutes, 1 hour, 2 hours, and 
3 hours postdose. At the end of each 6-week dosing period, 
PFT was performed 30 minutes prior to inhalation of trial 
medication and up to 24 hours after dosing (30 minutes, 
1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 
11 hours 50 minutes, 12 hours 30 minutes, 13 hours, 14 hours, 
22 hours, 23 hours, and 23 hours 50 minutes postdose). PFT 
up to 14 hours postdose was included to capture the peak 
associated with the evening dose of salmeterol + fluticasone 
propionate. PFT was performed using MasterScope® CT 
spirometers (ERT, Hoechberg, Germany), which complied 
with, and were calibrated daily in accordance with, the 
criteria of the American Thoracic Society and European 
Respiratory Society.23 AEs and concomitant therapies were 
recorded from screening through to follow-up.
Statistical analysis
Efficacy analyses were performed for all participants who 
received at least one dose of trial medication and had both 
baseline and postbaseline measurements for the primary 
end point, defined as the full analysis set. The per-protocol 
analysis set was defined as all participants without any 
important protocol deviations related to efficacy in any treat-
ment period. If the number of participants in the per-protocol 
analysis set was 90% of those in the full analysis set, the 
primary efficacy analyses were to be performed on the per-
protocol analysis set, as supportive analyses. All treated 
participants were included in the safety analyses.
For the primary end point of FEV
1
 AUC
0–12
 response and 
key secondary end point of FEV
1
 AUC
0–24
 response, response 
is defined as change from patient baseline. Patient baseline 
values were obtained by calculating the mean of the period 
baseline values taken for each patient on the first day of 
each treatment period prior to administration of the morning 
dose. For the primary and secondary end points, hypotheses 
were tested in hierarchical order, each at the 5% level of 
significance (two-sided) to protect the overall probability 
of type I error at 0.05 (two-sided). For the primary and sec-
ondary end points, the changes from baseline (start of each 
treatment period) at 6 weeks were analyzed using a restricted 
maximum-likelihood-based mixed-effects repeated-measures 
model, including treatment and period as fixed effects, patient 
as random effect, and period baseline and patient baseline 
as covariates. Compound symmetry was used as a covariate 
structure for within-patient variation. The SAS procedure 
MIXED was used for the restricted maximum-likelihood 
estimation, and Kenward–Roger approximation was used for 
denominator degrees of freedom.24 Adjusted mean values as 
well as treatment comparisons are presented, together with 
95% confidence intervals.
Results
Patient disposition and baseline disease 
characteristics
Overall, 288 participants were enrolled in the study and 229 
were randomized to receive treatment (Figure 2); 59 partici-
pants were not randomized due to screening failure. Discon-
tinuation from study medication was low (nine participants 
did not complete any treatment arm); primary reasons for 
discontinuation were AEs and noncompliance (Figure 2).
In the treated population, the majority of participants 
were male (64.6%) and white (99.6%), and almost half of 
participants were smokers at the time of the study (44.5%) 
(Table 1). Most participants had GOLD 2 lung function 
impairment (72.1%) and the remainder had GOLD 3 (27.9%). 
Participants were highly treated prior to the study; the 
most frequently recorded baseline pulmonary medications 
were LAMA (53.7%), short-acting β-agonist (53.3%), and 
LABA + ICS (38.0%) (Table 1).
Efficacy
FEV
1
 AUC
0–12
 (primary end point), FEV
1
 AUC
0–24
, and FEV
1
 
AUC
12–24
 after 6 weeks of treatment were increased from 
baseline by 120 mL in all treatment arms, with greater 
increases at both dose levels of once-daily tiotropium + 
olodaterol compared to twice-daily salmeterol + fluticasone 
propionate. Responses appeared to be similar for the two dose 
levels of tiotropium + olodaterol and salmeterol + fluticasone 
propionate (Table 2). Treatment comparisons for the primary 
end point revealed statistically significant improvements in 
FEV
1
 AUC
0–12
 with either dose of tiotropium + olodaterol 
compared to either dose of salmeterol + fluticasone propi-
onate, ranging from +103 mL to +129 mL (P0.0001 for 
all comparisons).
Tiotropium + olodaterol showed improved FEV
1
 
values over the full 24-hour dosing interval compared to 
salmeterol + fluticasone propionate after 6 weeks of treatment 
(Figure 3). Accordingly, analysis of the key secondary end 
point of FEV
1
 AUC
0–24
 response showed significantly greater 
improvements with either dose of tiotropium + olodaterol 
versus either dose of salmeterol + fluticasone propionate, 
ranging from +65 mL to +86 mL (P0.0001 for all 
comparisons) (Table 3). Improvements in FEV
1
 AUC
12–24
 
response after 6 weeks of treatment were also significantly 
greater with tiotropium + olodaterol compared to salmeterol + 
fluticasone propionate (P0.05 for all comparisons) (Table 3). 
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There was a trend for greater improvement in FEV
1
 AUC 
parameters
 
with tiotropium + olodaterol 5/5 µg compared to 
either dose of salmeterol + fluticasone than with tiotropium + 
olodaterol 2.5/5 µg compared to salmeterol + fluticasone 
(Table 3).
The peak
0–3
 FEV
1
 responses at Day 1 and Day 43 and 
trough FEV
1
 responses after 6 weeks of treatment for tiotro-
pium + olodaterol and salmeterol + fluticasone propionate 
are shown in Table 4. At the end of the 6-week treatment 
period (Day 43), tiotropium + olodaterol improved peak
0–3
 
FEV
1
 response by +111 mL to +147 mL compared to 
salmeterol + fluticasone propionate (P0.0001 for all com-
parisons) (Table 5). Notably, tiotropium + olodaterol also 
gave greater improvements in trough FEV
1
 after 6 weeks of 
treatment compared to both doses of salmeterol + fluticasone 
propionate, with improvements of +58 mL and +54 mL with 
tiotropium + olodaterol 5/5 µg and 2.5/5 µg, respectively, 
versus salmeterol + fluticasone propionate 50/500 µg 
(P0.001 for all comparisons) (Table 5).
Changes in FVC after 6 weeks of treatment were sig-
nificantly greater with tiotropium + olodaterol compared 
to salmeterol + fluticasone propionate, measured as FVC 
AUC
0–12
, FVC AUC
0–24
, FVC AUC
12–24
, and FVC AUC
0–3
, 
trough FVC, and peak
0–3
 FVC responses (P0.0001 for all 
comparisons of tiotropium + olodaterol versus salmeterol + 
fluticasone propionate). The improvement in FVC with 
tiotropium + olodaterol compared to salmeterol + fluticasone 
propionate was maintained over the full 24-hour dosing 
interval (Figure 4 and Tables S2 and S3).
Safety
Overall, the frequency of AEs was similar between all treat-
ment groups, with 29.7%–37.0% of participants reporting 
at least one AE while on treatment. The most common 
AEs were COPD worsening, nasopharyngitis, and cough 
(Table 6). Severe AEs were recorded in 5% of participants 
and AEs leading to discontinuation occurred in 3% of 
participants in each treatment group. Serious AEs occurred 
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Figure 2 Patient disposition.
Notes: aNine patients did not complete any treatment; bincludes lack of efficacy; ccompleting 1 treatment arm.
Abbreviation: ae, adverse event.
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in 4.1% of participants. There were two serious AEs lead-
ing to death in the tiotropium + olodaterol 5/5 µg group, one 
of which was a cerebral hemorrhage in a predisposed patient 
and the other occurred 19 days after the last dose of study 
treatment, with unknown cause (Table 6).
Discussion
In this study, once-daily tiotropium + olodaterol improved 
lung function to a greater extent than twice-daily 
salmeterol + fluticasone propionate, demonstrating significant 
improvements in the primary end point of FEV
1
 AUC
0–12
 and 
all other measures of lung function. Importantly, superiority 
in lung function improvement with once-daily tiotropium + 
olodaterol compared to twice-daily salmeterol + fluticasone 
propionate was demonstrated over the full 24-hour dosing 
period. These results add to the 24-hour lung function pro-
file of tiotropium + olodaterol from the VIVACITO® study. 
In addition, ENERGITO® included PFT measurements 
between 12 hours and 14 hours to account for the evening dose 
of salmeterol + fluticasone propionate; this testing schedule 
provided more rigorous testing over the full dosing interval 
compared to previous tiotropium + olodaterol studies.
Of particular note, the improvement in FEV
1
 AUC
0–12
 
with tiotropium + olodaterol versus salmeterol + fluticasone 
propionate in our study was similar to the increases seen with 
indacaterol + glycopyrrolate, another once-daily maintenance 
treatment, which was compared to twice-daily salmeterol-
fluticasone in the recent ILLUMINATE study of participants 
with moderate-to-severe COPD.1
Also of note were the significant improvements in all 
FVC parameters with tiotropium + olodaterol compared to 
salmeterol + fluticasone propionate. These improvements 
indicate a greater reduction in air trapping, and, therefore, 
lung hyperinflation, with tiotropium + olodaterol compared 
to salmeterol + fluticasone propionate. Furthermore, FVC 
parameters are associated with small-airways dysfunction, 
common in COPD; FVC responsiveness with tiotropium + 
olodaterol may indicate a specific improvement in the small 
airways following treatment.25
Optimization of lung function is an important treatment 
goal through the course of COPD, and there is a strong 
rationale to provide these benefits from the point at which 
individuals are identified as needing initiation of mainte-
nance treatment. Although measures of symptomology and 
health-related quality of life are required, improvements 
in lung function measures have been shown to predict 
improvements in patient-reported outcomes, as well as risk 
of exacerbation.26 While this study did not include health 
status or symptomatic end points, four large studies have 
demonstrated that improvements in lung function with 
tiotropium + olodaterol are accompanied by clinically mean-
ingful improvements in St George’s Respiratory Question-
naire score.9,27 In addition, an exploratory analysis from the 
TONADO® studies suggested a trend toward improvement 
in exacerbations;9 a large ongoing 52-week study will define 
the impact of tiotropium + olodaterol on exacerbation risk 
(DYNAGITO®; NCT02296138; 1237.19). The lung function 
Table 1 Demographic and baseline patient characteristics (treated 
population)
Total (n=229)
Sex, n (%)
Male 148 (64.6)
Female 81 (35.4)
Race, n (%)
White 228 (99.6)
asian 1 (0.4)
Region, n (%)
Western europe 169 (73.8)
eastern europe 60 (26.2)
Mean (SD) age, years 63.6 (7.6)
Alcohol history, n (%)
nondrinker 58 (25.3)
Drinker 171 (74.7)
Smoking status, n (%)
Ex-smoker 127 (55.5)
Current smoker 102 (44.5)
Mean (SD) smoking history, pack-years 39.1 (18.3)
Mean (SD) prebronchodilator screening
FeV1, l 1.425 (0.456)
% of predicted normal FeV1, l 49.490 (12.228)
Mean (SD) postbronchodilator screening
FeV1, l 1.624 (0.468)
% of predicted normal FeV1, l 56.436 (11.812)
GOLD, n (%)
1 (80%) 0
2 (50–80%) 165 (72.1)
3 (30–50%) 64 (27.9)
4 (30%) 0
Baseline pulmonary medication, n (%)
LAMA 123 (53.7)
SABA 122 (53.3)
LABA/ICS 87 (38.0)
LABA 54 (23.6)
SAMA 24 (10.5)
ICs 22 (9.6)
Xanthines 11 (4.8)
Mucolytics 5 (2.2)
Oral β-adrenergics 2 (0.9)
Oxygen 1 (0.4)
steroids, other 1 (0.4)
Abbreviations: FeV1, forced expiratory volume in 1 second; GOLD, Global initiative 
for chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LABA, long-acting 
β2-agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting β-agonist; 
SAMA, short-acting muscarinic antagonist; SD, standard deviation.
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Table 2 Adjusted mean FEV1 AUC responses after 6 weeks of treatment (full analysis set)
Tiotropium + 
olodaterol 5/5 µg
Tiotropium + 
olodaterol 2.5/5 µg
Salmeterol + fluticasone 
propionate 50/500 µg
Salmeterol + fluticasone 
propionate 50/250 µg
Patients, n 216 214 217 211
Adjusted mean (SE) FEV1 
AUC0–12 response, ml
317 (14) 295 (14) 188 (14) 192 (15)
Adjusted mean (SE) FEV1 
AUC0–24 response, ml
244 (14) 228 (14) 159 (14) 162 (14)
Adjusted mean (SE) FEV1 
AUC12–24 response, ml
172 (14) 160 (14) 129 (14) 132 (14)
Notes: The adjusted mean (SE) was obtained from fitting a mixed-effects repeated-measures model including the following: fixed effects of treatment and period; period 
baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within-patient variation; and Kenward–Roger 
approximation of denominator degrees of freedom.
Abbreviations: AUC, area under the curve; AUC0–12, AUC from 0 hour to 12 hours; AUC0–24, AUC from 0 hour to 24 hours; AUC12–24, AUC from 12 hours to 24 hours; 
FeV1, forced expiratory volume in 1 second; SE, standard error.
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Figure 3 Adjusted mean 24-hour FEV1 profile after 6 weeks of treatment (full analysis set).
Abbreviations: bid, twice daily; F, fluticasone propionate; FEV1, forced expiratory volume in 1 second; O, olodaterol; qd, once daily; S, salmeterol; T, tiotropium.
Table 3 Adjusted mean FEV1 AUC0–12, AUC0–24, and AUC12–24 responses after 6 weeks of treatment, showing the treatment differences 
(full analysis set)
Treatment comparison
Tiotropium + olodaterol 5/5 µg versus Tiotropium + olodaterol 2.5/5 µg versus
Salmeterol + fluticasone 
propionate 50/500 µg
Salmeterol + fluticasone 
propionate 50/250 µg
Salmeterol + fluticasone 
propionate 50/500 µg
Salmeterol + fluticasone 
propionate 50/250 µg
FeV1 AUC0–12, ml
Adjusted mean (SE) 129 (11) 125 (11) 106 (11) 103 (11)
95% CI 107, 150 103, 147 85, 128 81, 124
P-value 0.0001 0.0001 0.0001 0.0001
FeV1 AUC0–24, ml
Adjusted mean (SE) 86 (11) 82 (11) 69 (11) 65 (11)
95% CI 65, 107 61, 103 48, 90 45, 86
P-value 0.0001 0.0001 0.0001 0.0001
FeV1 AUC12–24, ml
Adjusted mean (SE) 43 (11) 39 (12) 32 (11) 28 (11)
95% CI 21, 65 17, 62 9, 54 6, 51
P-value 0.0002 0.0007 0.0055 0.0146
Notes: The adjusted mean (SE) was obtained from fitting a mixed-effects repeated-measures model including the following: fixed effects of treatment and period; period 
baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within-patient variation; and Kenward–Roger 
approximation of denominator degrees of freedom.
Abbreviations: AUC, area under the curve; AUC0–12, AUC from 0 hour to 12 hours; AUC0–24, AUC from 0 hour to 24 hours; AUC12–24, AUC from 12 hours to 24 hours; 
CI, confidence interval; FEV1, forced expiratory volume in 1 second; SE, standard error.
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Table 4 Peak0–3 FeV1 response at study Day 1 and Day 43 and trough FEV1 responses after 6 weeks of treatment (full analysis set)
Tiotropium +  
olodaterol 5/5 µg
Tiotropium +  
olodaterol 2.5/5 µg
Salmeterol + fluticasone 
propionate 50/500 µg
Salmeterol + fluticasone 
propionate 50/250 µg
Patients, n 218 215 218 211
Adjusted mean (SE) peak0–3 
FeV1 response, ml
Day 1 345 (12) 326 (12) 265 (12) 250 (12)
Day 43 432 (16) 401 (16) 285 (15) 291 (16)
Patients, n 216 214 217 211
Adjusted mean (SE) trough 
FeV1 response, ml
197 (14) 192 (14) 139 (14) 150 (14)
Notes: The adjusted mean (SE) was obtained from fitting a mixed-effects repeated-measures model including the following: fixed effects of treatment and period; period 
baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within-patient variation; and Kenward–Roger 
approximation of denominator degrees of freedom.
Abbreviations: FeV1, forced expiratory volume in 1 second; peak0–3 FeV1, peak forced expiratory volume in 1 second from 0 hour to 3 hours; SE, standard error.
Table 5 Peak0–3 FeV1 response at study Day 1 and Day 43 and trough FEV1 responses after 6 weeks of treatment, showing the 
differences between treatments (full analysis set)
Treatment comparison
Tiotropium + olodaterol 5/5 µg versus Tiotropium + olodaterol 2.5/5 µg versus
Salmeterol + fluticasone 
propionate 50/500 µg
Salmeterol + fluticasone 
propionate 50/250 µg
Salmeterol + fluticasone 
propionate 50/500 µg
Salmeterol + fluticasone 
propionate 50/250 µg
Peak0–3 FeV1, mL, Day 1
Adjusted mean (SE) 80 (9) 95 (9) 61 (9) 76 (9)
95% CI 62, 97 77, 112 44, 79 59, 94
P-value 0.0001 0.0001 0.0001 0.0001
Peak0–3 FeV1, mL, Day 43
Adjusted mean (SE) 147 (12) 142 (12) 116 (12) 111 (12)
95% CI 123, 171 118, 166 92, 140 87, 135
P-value 0.0001 0.0001 0.0001 0.0001
Trough FeV1, ml
Adjusted mean (SE) 58 (12) 47 (12) 54 (12) 42 (12)
95% CI 34, 82 22, 71 29, 78 18, 67
P-value 0.0001 0.0002 0.0001 0.0007
Notes: The adjusted mean (SE) was obtained from fitting a mixed-effects repeated-measures model including the following: fixed effects of treatment and period; period 
baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within-patient variation; and Kenward–Roger 
approximation of denominator degrees of freedom.
Abbreviations: CI, confidence interval; FEV1, forced expiratory volume in 1 second; peak0–3 FeV1, peak forced expiratory volume in 1 second from 0 hour to 3 hours; 
se, standard error.
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Figure 4 Adjusted mean 24-hour FVC profile after 6 weeks of treatment (full analysis set).
Abbreviations: bid, twice daily; F, fluticasone propionate; FVC, forced vital capacity; O, olodaterol; qd, once daily; S, salmeterol; T, tiotropium.
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Table 6 Summary of AEs (treated population)
Tiotropium +  
olodaterol 5/5 µg, 
n (%)
Tiotropium +  
olodaterol 2.5/5 µg, 
n (%)
Salmeterol + fluticasone 
propionate 50/500 µg,  
n (%)
Salmeterol + fluticasone 
propionate 50/250 µg,  
n (%)
Total,  
n (%)
Patients 221 (100) 215 (100) 219 (100) 212 (100) 229 (100)
Any AE 75 (33.9) 74 (34.4) 81 (37.0) 63 (29.7) 158 (69.0)
severe aes 6 (2.7) 7 (3.3) 11 (5.0) 5 (2.4) 24 (10.5)
Drug-related AEsa 6 (2.7) 12 (5.6) 9 (4.1) 9 (4.2) 23 (10.0)
Other significant AEsb 4 (1.8) 3 (1.4) 2 (0.9) 0 (0.0) 9 (3.9)
aes leading to discontinuation 
of trial drug
6 (2.7) 4 (1.9) 3 (1.4) 2 (0.9) 15 (6.6)
serious aes 7 (3.2) 6 (2.8) 9 (4.1) 4 (1.9) 22 (9.6)
Fatal aes 2 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.9)
Immediately life-threatening 
aes
0 (0.0) 1 (0.5) 0 (0.0) 0 (0.0) 1 (0.4)
Requiring hospitalization 5 (2.3) 6 (2.8) 9 (4.1) 4 (1.9) 20 (8.7)
Prolonged hospitalization 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 1 (0.4)
aes occurring in 2% of 
patients overallc
COPD worsening 20 (9.0) 12 (5.6) 19 (8.7) 9 (4.2) 45 (19.7)
Nasopharyngitis 12 (5.4) 12 (5.6) 11 (5.0) 13 (6.1) 40 (17.5)
Cough 7 (3.2) 5 (2.3) 5 (2.3) 4 (1.9) 17 (7.4)
Dyspnea 3 (1.4) 3 (1.4) 6 (2.7) 4 (1.9) 14 (6.1)
headache 8 (3.6) 5 (2.3) 2 (0.9) 4 (1.9) 14 (6.1)
Back pain 4 (1.8) 2 (0.9) 2 (0.9) 4 (1.9) 11 (4.8)
Dysphonia 0 (0.0) 3 (1.4) 3 (1.4) 2 (0.9) 7 (3.1)
arthralgia 1 (0.5) 2 (0.9) 2 (0.9) 2 (0.9) 6 (2.6)
Diarrhea 1 (0.5) 2 (0.9) 1 (0.5) 2 (0.9) 5 (2.2)
nausea 1 (0.5) 0 (0.0) 2 (0.9) 2 (0.9) 5 (2.2)
Oropharyngeal pain 1 (0.5) 2 (0.9) 2 (0.9) 0 (0.0) 5 (2.2)
Pneumonia 1 (0.5) 2 (0.9) 1 (0.5) 1 (0.5) 5 (2.2)
Notes: aDrug-related AEs were defined by the investigator; baccording to ICH E3; cpercentages were calculated using the total number of patients per treatment group as 
the denominator.
Abbreviations: AE, adverse event; COPD, chronic obstructive pulmonary disease; ICH E3, International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use, Harmonised Tripartite Guideline E3.
results from the current study are also broadly in line with 
another study suggesting that LABA + ICS may not be the 
most effective treatment for improving lung function in 
individuals with moderate-to-severe COPD.1 In that study, 
a greater lung function response with indacaterol + glyco-
pyrronium versus salmeterol + fluticasone was accompanied 
by a significant treatment-corrected difference in Transition 
Dyspnea Index focal score, but no difference in St George’s 
Respiratory Questionnaire score.
One potential limitation of the study is that it cannot 
be interpreted directly in the context of the current GOLD 
recommendations for treatment options, wherein individuals 
are grouped according to airflow limitation, exacerbation 
risk, symptoms, and breathlessness (GOLD patient groups 
A–D).2 Inclusion in the ENERGITO® study was based on 
the spirometric assessment of severity of airflow limitation 
used in an earlier version of the GOLD strategy report;22 
participants with GOLD 2 and 3 (moderate and severe) 
COPD were screened and patient symptoms or exacerbation 
risk were not assessed as enrollment criteria. Regardless of 
this, the findings suggest that tiotropium + olodaterol pro-
vides lung function benefits in a representative population 
with moderate-to-severe COPD and that response to treat-
ment is not affected by the prior use or type of maintenance 
treatment.
In this study, there was no apparent difference in lung 
function response between the two doses of salmeterol + 
fluticasone propionate tested (50/250 µg and 50/500 µg). This 
observation was similar to that seen in the recent WISDOM 
study, which assessed the effect of stepwise withdrawal of 
ICS from a regimen containing tiotropium, salmeterol, and 
fluticasone propionate. In the WISDOM study, there was 
no change in lung function when the twice-daily dose of 
fluticasone propionate was reduced from 500 µg to 250 µg, 
although participants were only observed on the 250 µg dose 
for a period of 6 weeks. Complete cessation of fluticasone 
propionate resulted in a modest decrease in lung function.28 
These observations raise the question of whether only a low 
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dose of ICS is required to achieve potential lung function 
improvement with these agents.
Conclusion
For individuals with moderate-to-severe COPD who require 
maintenance treatment with the goal of improving lung 
function, with associated symptomatic and health-status 
benefits, tiotropium + olodaterol should be considered as 
another treatment option that offers better lung function opti-
mization than LABA + ICS. While tiotropium + olodaterol 
has demonstrated clinically significant improvements in 
symptoms and quality of life versus placebo,27 further studies 
are warranted to confirm whether the additional improve-
ments of tiotropium + olodaterol relative to LABA + ICS 
demonstrated in this study translate into additional clinically 
relevant benefits for individuals.
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Table S1 additional exclusion criteria
Patients with any of the following conditions were to be excluded:
A diagnosis of thyrotoxicosis (due to the known class side-effect profile of β2-agonists)
A diagnosis of paroxysmal tachycardia (100 beats/min) (due to the known class side-effect profile of β2-agonists)
A history of myocardial infarction within 1 year of the screening visit
Unstable or life-threatening cardiac arrhythmia
Hospitalization for heart failure within the past year
Known active tuberculosis
A malignancy for which the patient has undergone resection, radiation therapy, or chemotherapy within the past 5 years (except for treated basal 
cell carcinoma)
A history of life-threatening pulmonary obstruction
A history of cystic fibrosis
Clinically evident bronchiectasis
A history of significant alcohol or drug abuse
Patients who have undergone thoracotomy with pulmonary resection
Patients being treated with oral or patch β-adrenergics
Patients being treated with oral corticosteroid medication within 6 weeks prior to Visit 1
Patients who regularly use daytime oxygen therapy for 1 hour per day and, in the investigator’s opinion, will be unable to abstain from the use of 
oxygen therapy during clinic visits
Patients who have completed a pulmonary rehabilitation program in the 6 weeks prior to the screening visit or patients who are currently in a 
pulmonary rehabilitation program
Patients who have taken an investigational drug within 1 month, 6 half-lives, or within the washout period (whichever is greater) prior to screening 
visit (Visit 1)
Patients with known hypersensitivity to β-adrenergic drugs, BAC, EDTA, or any other component of the Respimat® inhalation solution, or lactose 
monohydrate
Pregnant or nursing women
Women of childbearing potential not using a highly effective method of birth control.a Female patients will be considered to be of childbearing 
potential unless surgically sterilized by hysterectomy or bilateral tubal ligation or if in postmenopausal stage for 2 years
Patients who have previously been randomized in this study or are currently participating in another study
Patients who are unable to comply with pulmonary medication restrictions prior to randomization
Notes: aDefined as those methods that result in a low failure rate (ie, 1% per year) when used consistently and correctly as defined by the International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use – Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical 
Trials and Marketing Authorization for Pharmaceuticals M3(R2) guidelines.
Abbreviations: BAC, benzalkonium chloride; EDTA, ethylenediaminetetraacetic acid.
Table S2 Adjusted mean FVC AUC0–12, AUC0–24, and AUC12–24 responses after 6 weeks of treatment: treatment differences 
(full analysis set)
Treatment comparison
Tiotropium + olodaterol 5/5 µg versus Tiotropium + olodaterol 2.5/5 µg versus
Salmeterol + fluticasone 
propionate 50/500 µg
Salmeterol + fluticasone 
propionate 50/250 µg
Salmeterol + fluticasone 
propionate 50/500 µg
Salmeterol + fluticasone 
propionate 50/250 µg
FVC AUC0–12, ml
Adjusted mean (SE) 218 (18)* 215 (18)* 183 (18)* 180 (18)*
95% CI 184, 253 180, 250 149, 218 146, 215
FVC AUC0–24, ml
Adjusted mean (SE) 176 (17)* 177 (17)* 140 (17)* 141 (17)*
95% CI 144, 209 144, 209 108, 173 108, 173
FVC AUC12–24, ml
Adjusted mean (SE) 135 (18)* 138 (18)* 98 (18)* 101 (18)*
95% CI 100, 170 103, 174 63, 133 66, 136
Notes: *P0.0001. The adjusted mean (SE) was obtained from fitting a mixed-effects repeated-measures model including the following: fixed effects of treatment and period; 
period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within-patient variation; and Kenward–Roger 
approximation of denominator degrees of freedom.
Abbreviations: AUC0–12, area under the curve from 0 hour to 12 hours; AUC0–24, area under the curve from 0 hour to 24 hours; AUC12–24, area under the curve from 
12 hours to 24 hours; CI, confidence interval; FVC, forced vital capacity; SE, standard error.
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Tiotropium + olodaterol 24-hour lung function profile
Table S3 Adjusted mean FVC AUC0–3, trough FVC, and peak0–3 FVC responses after 6 weeks of treatment: treatment differences 
(full analysis set)
Treatment comparison
Tiotropium + olodaterol 5/5 µg versus Tiotropium + olodaterol 2.5/5 µg versus
Salmeterol + fluticasone 
propionate 50/500 µg
Salmeterol + fluticasone 
propionate 50/250 µg
Salmeterol + fluticasone 
propionate 50/500 µg
Salmeterol + fluticasone 
propionate 50/250 µg
FVC AUC0–3, ml
Adjusted mean (SE) 104 (13)* 110 (13)* 82 (13)* 88 (13)*
95% CI 78, 130 84, 136 56, 108 62, 114
Trough FVC, ml
Adjusted mean (SE) 145 (20)* 137 (20)* 120 (20)* 112 (20)*
95% CI 106, 183 98, 176 81, 158 74, 151
Peak0–3 FVC response, ml
Adjusted mean (SE) 215 (20)* 213 (20)* 172 (20)* 169 (20)*
95% CI 176, 255 173, 253 133, 211 130, 209
Notes: *P0.0001. The adjusted mean (SE) was obtained from fitting a mixed-effects repeated-measures model including the following: fixed effects of treatment and period; 
period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within-patient variation; and Kenward–Roger 
approximation of denominator degrees of freedom.
Abbreviations: AUC0–3, area under the curve from 0 hour to 3 hours; CI, confidence interval; FVC, forced vital capacity; peak0–3 FVC, peak forced vital capacity from 0 hour to 
3 hours; SE, standard error.
